Nasdaq GlobeNewswire

Abiomed Surpasses 50,000 Impella® Patients Treated in the United States

Del

DANVERS, Mass., 2017-02-23 20:02 CET (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced that it has supported more than 50,000 patients in the U.S. with its Impella® line of heart pumps. Impella heart pumps enable minimally invasive treatment for high risk heart failure patients who might otherwise have no treatment options.

The 50,000th patient supported with an Impella device was treated by Dr. Subhash Banerjee, Professor of Medicine at the University of Texas Southwest Medical Center and Chief of Cardiology at the Dallas VA Medical Center. "Impella heart pumps enable percutaneous treatment options for high risk heart failure patients who have been turned-down for surgery," said Dr. Banerjee, who performed the procedure with the Impella CP®. "Hemodynamic stability is essential to treating these types of high risk patients and with the support of an Impella device, we are able to safely perform complete and complex coronary interventions on patients that might not have been treated previously.”

Impella heart pumps are the first and only temporary percutaneous ventricular support devices that are FDA-approved as safe and effective for use in high-risk percutaneous coronary interventions (PCI) as well as the treatment of cardiogenic shock, a life-threatening condition that typically occurs during or after a heart attack, or post-cardiopulmonary bypass surgery.

Heart failure and coronary heart disease are the number one cause of death in the United States, causing one out of every three deaths, or nearly 900,000 deaths each year.1 This heart failure epidemic currently affects 5.7 million Americans and by the year 2030 that number is expected to grow by 46 percent.1,2   While, to date, over 50,000 patients have been treated with Impella in the United States, Impella is currently used in only 1 percent of PCIs and in less than 10 percent of patients experiencing an AMI complicated by cardiogenic shock. As a result, tens of thousands of patients remain undertreated and potentially unaware of the procedural options Impella can afford physicians.

In Detroit, an unprecedented collaboration between metro cardiologists across five hospitals is providing an early indication of the potential to improve heart attack survival rates using Impella early in the cardiogenic shock spiral.

“People are aware that heart disease is the number one killer, but they may not know what a major role coronary artery disease plays in the development of cardiogenic shock, which has had the same devastating mortality rate for 30 years in spite of the major advances in cardiac care," said William W. O’Neill, M.D., director of the Center for Structural Heart Disease at Henry Ford Health System. "In our collaborative approach crossing the usual hospital system boundaries, we have utilized a common protocol since July 2016 in an effort to improve the outcomes for our entire community.”  

Continued Dr. O’Neill: “In reviewing the observational data generated from treating a small group of 30 patients, we continue to develop and prove the hypothesis that Impella, used early, can be an effective tool to improve survival of cardiogenic shock and enable patients to keep their own hearts after events that may otherwise have resulted in transplant, chronic heart failure, or death.” These results and other data observed in Abiomed’s IQ Assurance Database will be discussed in March at the annual American College of Cardiology Scientific Sessions in Washington, D.C.

The Impella pumps offer the unique ability to both stabilize the patient's hemodynamics before or during a percutaneous coronary intervention (PCI) procedure and unload the heart, which allows the muscle to rest and potentially recover its native function. Impella is now recognized by multiple medical guidelines and regulatory bodies worldwide and is supported in published expert consensus documents and nearly 400 clinical publications. Heart recovery is the ideal option for patient quality of life and, as documented in several clinical papers, has the ability to save costs for the healthcare system3,4,5.

In 2014, a study analyzed all adult patients receiving short-term mechanical circulatory support (MCS) in the United States from 2004 to 2011 (12,000 patients) using the Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project. The study showed the use of short term mechanical support in the U.S. had reduced hospital mortality rates while also reducing hospital costs.6 Additionally, Impella has been shown to reduce length of stay7, reduce readmission rates8 and has been proven cost effective in multiple clinical studies.9

“Treating 50,000 patients in the United States is an incredible milestone for the Company, as it reflects our unyielding commitment to addressing the significant unmet need for advanced heart failure patients who might otherwise have no treatment options,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “By working to change the standard of care and building the field of heart recovery, it is our goal to continue to improve patient outcomes and increase access to this life-changing innovation.”

Founded in 1981 in Danvers, Massachusetts, Abiomed develops and manufactures Impella, a line of the world's smallest heart pumps that are inserted minimally invasively in a hospital catheterization lab without the need for surgery. The Impella heart pumps are in over 1,200 U.S. hospitals and are used in 98% of the top U.S. heart hospitals.

ABOUT IMPELLA
The Impella 2.5®, Impella CP® and Impella 5.0® are FDA-approved to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP® are also approved to treat certain advanced heart failure patients undergoing elective percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP®, is approved to treat certain patients experiencing right heart failure.

To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com.

The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP are registered trademarks of Abiomed, Inc. in the U.S. and in certain foreign countries. Impella 2.5, Impella 5.0, and Recovering hearts. Saving lives. are trademarks of Abiomed, Inc.
                        
ABOUT ABIOMED 
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS 
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

  1. American Heart Association: Heart Disease and Stroke Statistics; 2015 Update
  2. Cardiovascular Business: Heart failure expected to steadily rise through 2030 ; Jan 30, 2017 http://www.cardiovascularbusiness.com/topics/heart-failure/heart-failure-expected-steadily-rise-through-2030
  3. Maini B, Gregory D, Scotti DJ, Buyantseva L. Percutaneous cardiac assist devices compared with surgical hemodynamic support alternatives: Cost-Effectiveness in the Emergent Setting. Catheter Cardiovasc Interv. 2014 May 1;83(6):E183-92.
  4. Cheung A, Danter M, Gregory D. TCT-385 Comparative Economic Outcomes in Cardiogenic Shock Patients Managed with the Minimally Invasive Impella or Extracorporeal Life Support. J Am Coll Cardiol. 2012;60(17_S):. doi:10.1016/j.jacc.2012.08.413.
  5. Gregory D, Scotti DJ, de Lissovoy G, Palacios I, Dixon, Maini B, O'Neill W. A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention. Am Health Drug Benefits. 2013 Mar;6(2):88-99
  6. Stretch et al, Journal of the American College of Cardiology, 2014
  7. Gregory D, et al. Am Health Drug Benefits. 2013;6(2):88-99; Maini B, et al. Catheter Cardiovasc Interv. 2014;83(6):E183-E192.
  8. Gregory D, et al. Am Health Drug Benefits. 2013;6(2):88-99; Gregory D, Scotti DJ. J Manag Care Med. 2013:16(1):61-69; Maini B, et al. Expert Rev Pharmacoecon Outcomes Res. 2014;14(3):403-416. ; Gregory DA, et al. J Am Coll Cardiol. 2014;63(12_S):A925.
  9. Gregory D, et al. Am Health Drug Benefits. 2013;6(2):88-99; Maini B, et al. Catheter Cardiovasc Interv. 2014;83(6):E183-E192; Roos JB, et al. J Med Econ. 2013;16(3):381-390.

         For further information please contact:
         
         Ingrid Goldberg
         Director, Investor Relations
         978-646-1590
         igoldberg@abiomed.com
         
         Adrienne Smith
         Senior Director, Public Relations and Corporate Communications
         978-646-1553
         adsmith@abiomed.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit15.12.2017 22:04Pressemelding

Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Ltd. (Nasdaq:OXFD) and QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt Stock Exchange:QIA) announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN's QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products. Under terms of the agreement, all pending claims between Oxford and QIAGEN and the co-defendants have been resolved. As part of the settlement, Oxford has granted QIAGEN a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million.  The settlement includes general

Algeco Scotsman Announces Acquisition of Iron Horse Ranch15.12.2017 21:32Pressemelding

BALTIMORE, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Algeco/Scotsman Holding S.à r.l. (together with its subsidiaries, the "Algeco Group") today announced the successful closing of the acquisition by the Algeco Group's subsidiary, Target Logistics Management, LLC ("Target Logistics"), of Iron Horse Ranch from funds managed by TDR Capital LLP ("TDR"). The acquisition solidifies Target Logistics' position as the single largest provider of turnkey workforce housing in the U.S., including a network of eight lodges and 2,119 beds in the Permian Basin. With the acquisition, Target Logistics' Permian Basin lodge network now includes Texas lodges in Pecos, Mentone, San Angelo and two in Odessa, along with two lodges in Carlsbad and Lovington, New Mexico. Additionally, Target Logistics adds Eagle Ford lodges in Cameron and Yorktown, Texas. Diarmuid Cummins, CEO Algeco Scotsman: "Today we announce the completion of the second of two strategic acquisitions which we flagged earlier

Elemica Named to Food Logistics Top 100 List15.12.2017 13:55Pressemelding

11th Consecutive Win for Delivering Value Across Clients' Supply Chains WAYNE, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Elemica, the leading  Business Network for the process industries, announces the company has been named to Food Logistics magazine's FL100+ Award for the 11th year. The FL100+ list recognizes leading software and technology providers in the food and beverage industry.  Elemica was chosen for helping agricultural and food ingredient businesses conduct more efficient and error free commerce across their community of suppliers, customers and logistics providers - delivering value through lower operating expenses and working capital costs. "We are honored to be included for the past eleven years on the Food Logistics FL100+ list for helping companies improve efficiencies and generate value from their supply chains," said John Blyzinskyj, CEO of Elemica. "Automating business processes, enabling end-to-end visibility, and providing a platform for

GSV Asset Management Announces Strategic Investment from HMC Capital-Led Group14.12.2017 21:03Pressemelding

WOODSIDE, Calif. and NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- GSV Asset Management, LLC ("GSV"), a modern merchant bank that identifies, advises, and invests in the fastest growing, most dynamic companies in the world - the Stars of Tomorrow - today announced a strategic investment from a group led by HMC Capital ("HMC"), a leading Latin American advisory and investment firm. While terms of the deal were not disclosed, the investment will result in a minority ownership interest for the HMC-led group in GSV Asset Management. Proceeds will be used to enhance GSV's ongoing investment activities, as well as to accelerate its strategic expansion into new business areas and geographies. "We are very excited to partner with HMC Capital, a multi-billion dollar asset manager that brings a range of complimentary capabilities to GSV Asset Management," said Michael Moe, founder of GSV. "GSV stands for Global Silicon Valley and our alliance with HMC reflects our shared commitment t

TrueCommerce Datalliance Releases Third 2017 Update for Vendor Managed Inventory Platform14.12.2017 19:28Pressemelding

Latest Software Update Enhances Browser, Productivity Experience CINCINNATI, Dec. 14, 2017 (GLOBE NEWSWIRE) -- TrueCommerce Datalliance, a leading vendor managed inventory service solutions provider, announced today that it released the third scheduled 2017 update to its VMI platform. The free update is part of TrueCommerce Datalliance's commitment to improving the functionality of its cloud-based supply chain software. Highlights of the release include several improvements to its system architecture and capabilities: Google Chrome is now officially supported Order Worksheets are now easier to view in Internet Explorer One-click access to recently changed or added items Mass Launch Order Preview lists all items suggested or added via allocation "We promise our customers three major updates every year," said Connie Shafer, TrueCommerce Datalliance Producti

ATTO announces support for Apple® Release of the new iMac Pro14.12.2017 18:37Pressemelding

ATTO's line of ThunderboltTM technology enabled products continue to revolutionize connectivity to storage AMHERST, N.Y., Dec. 14, 2017 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage and network connectivity and infrastructure solutions for data-intensive computing environments, today confirmed their continued commitment to the newly released line of product updates and innovations from Apple. With the powerful and new iMac Pro® now shipping, ATTO continues to support the new offerings from this industry leading manufacturer. "Our deep relationship with Apple over the last 30 years continues to drive our position as a leading force within the Apple community," said Timothy J. Klein, president and CEO at ATTO Technology. The iMac Pro sets a new standard for Apple design and performance and complements why users select ATTO products. As Apple pushes the boundaries of desktop computing, ATTO continues to provide industry leading products that op

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom